---
figid: PMC4134689__nihms600164f2
figlink: /pmc/articles/PMC4134689/figure/F2/
number: Figure 2
caption: 'Therapeutic strategies to target mutant NRAS: Direct targeting strategies
  include inhibition of RAS transcription by RNA interference and blockade of posttranslational
  modification by farnesyltransferase inhibitors. Agents that block downstream mitogen-activated
  protein kinase (MAPK) signaling include inhibitors of MAPK/ERK kinase (MEK) and
  extracellular signal–regulated kinase (ERK) as well as paradox-breaker RAF inhibitors.
  Agents targeting cell cycle regulation and the phosphoinositide 3-kinase (PI3K)–AKT
  pathway are also being evaluated in combination with MAPK pathway inhibitors. CDK,
  cyclin-dependent kinase; mTOR, mammalian target of rapamycin; Rb, retinoblastoma.'
pmcid: PMC4134689
papertitle: 'Molecular Pathways: Targeting NRAS in Melanoma and Acute Myelogenous
  Leukemia.'
reftext: Douglas B. Johnson, et al. Clin Cancer Res. ;20(16):4186-4192.
pmc_ranked_result_index: '19212'
pathway_score: 0.7791104
filename: nihms600164f2.jpg
figtitle: 'Therapeutic strategies to target mutant NRAS: Direct targeting strategies
  include inhibition of RAS transcription by RNA interference and blockade of posttranslational
  modification by farnesyltransferase inhibitors'
year: ''
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4134689__nihms600164f2.html
  '@type': Dataset
  description: 'Therapeutic strategies to target mutant NRAS: Direct targeting strategies
    include inhibition of RAS transcription by RNA interference and blockade of posttranslational
    modification by farnesyltransferase inhibitors. Agents that block downstream mitogen-activated
    protein kinase (MAPK) signaling include inhibitors of MAPK/ERK kinase (MEK) and
    extracellular signal–regulated kinase (ERK) as well as paradox-breaker RAF inhibitors.
    Agents targeting cell cycle regulation and the phosphoinositide 3-kinase (PI3K)–AKT
    pathway are also being evaluated in combination with MAPK pathway inhibitors.
    CDK, cyclin-dependent kinase; mTOR, mammalian target of rapamycin; Rb, retinoblastoma.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - AKT2
  - MAPK3
  - MAP2K2
  - PIK3CD
  - PIK3R4
  - BRAF
  - MAPK1
  - PIK3CG
  - MTOR
  - MAP2K1
  - PIK3CA
  - NRAS
  - PIK3R3
  - AKT3
  - ARAF
  - CDKN2A
  - CDK6
  - CDK4
  - PTEN
  - PIK3R6
  - RAF1
  - AKT1
  - PIK3R5
  - PIK3CB
  - GSK2141795
  - GDC-0941
  - Trametinib
  - Buparlisib
  - Cobimetinib
  - AZD5363
  - Binimetinib
  - Cancer
  - Lung cancer
genes:
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: NRAS
  symbol: NRAS
  source: hgnc_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: CDKN2A
  symbol: CDKN2A
  source: hgnc_symbol
  hgnc_symbol: CDKN2A
  entrez: '1029'
- word: CDK4/6
  symbol: CDK6
  source: hgnc_symbol
  hgnc_symbol: CDK6
  entrez: '1021'
- word: CDK4/6Inhibitors
  symbol: CDK4
  source: hgnc_symbol
  hgnc_symbol: CDK4
  entrez: '1019'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
chemicals:
- word: GSK2141795
  source: MESH
  identifier: C000595149
- word: GDC-0941
  source: MESH
  identifier: C532162
- word: Trametinib
  source: MESH
  identifier: C560077
- word: Buparlisib
  source: MESH
  identifier: C571178
- word: Cobimetinib
  source: MESH
  identifier: C574276
- word: AZD5363
  source: MESH
  identifier: C575618
- word: Binimetinib
  source: MESH
  identifier: C581313
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
---
